Delcath's Q2 Push Past $29M Revenue Makes the Headwinds Look Temporary

Recent revenue growth weakens the stall narrative

Delcath's latest quarter makes the recent pause in momentum look less convincing. The company's most recent reported quarter reached Q2 2026 revenue of $29.1 million, ahead of prior quarterly levels. HEPZATO KIT revenue, CHEMOSAT revenue, gross margin, adjusted EBITDA, and operating cash flow all remained meaningful, and the company still finished the quarter with a strong cash balance. That does not erase the operating wobble, but it does suggest the business is still generating real demand rather than relying only on future promise.

The profitability dip is real, but it may be temporary

Bears can still point to the margin between revenue growth and profitability. Adjusted EBITDA and operating cash flow both softened versus the prior year, which is fair criticism if investors want cleaner execution. Bulls can counter that core product revenue is still improving, gross margin held up better than expected, and the company is still funding expansion from a solid cash base. For now, that looks more like a growing-pains story than a broken business model.

Clinical interest is broadening beyond a single indication

The more important shift is where real-world use and clinical interest are showing up: liver-dominant metastatic breast cancer. Independent investigators presented ESMO Breast Cancer 2026 feasibility and safety data from a 15-patient retrospective cohort. The evidence here is early and hypothesis-generating, not definitive, but it does suggest a plausible treatment niche in a population with limited options.

Delcath has also moved beyond single-country curiosity. Registered studies now span both metastatic breast cancer and metastatic colorectal cancer. The breast cancer network includes major U.S. centers plus IEO Milan in Europe. The colorectal network is broader still, with sites across the U.S. and Europe. That is a meaningful expansion in clinical footprint, even if it still falls short of proof of commercial impact.

What would strengthen confidence

Investable conviction still depends on formal trial results matching these early signals. Over the next few quarters, the more important watchpoints are:

• Whether ongoing trials accrue on schedule
• Whether early clinical signals begin to appear in prospective data
• Whether site activation continues to translate into consistent patient exposure

If those checkpoints improve, the case looks more like a repeatable liver-focused platform. If they do not, the story stays closer to a promising device with unresolved proof points.

Phase 2 trials are the next valuation test

The recent operating improvement is a bridge, not the finish line. What matters now is whether Delcath can move the market from quarter-to-quarter noise to a clearer catalyst sequence.

DELUMA and the colorectal program set the next scorecard

In DELUMA, the first patient was dosed in Milan for liver-dominant HER2-negative metastatic breast cancer. The trial is designed to enroll approximately 90 patients at more than 20 sites across the U.S. and Europe, with hepatic progression-free survival as the primary endpoint. That is a cleaner valuation setup than relying only on early single-arm data.

The colorectal program is moving through the same gate. The first patient was dosed at City of Hope in the global Phase 2 trial of HEPZATO plus standard of care in liver-dominant metastatic colorectal cancer. It also calls for approximately 90 patients and will run at more than 20 sites in the U.S. and Europe. The primary readout window is mid-2028 for hepatic progression-free survival, with overall survival expected in late 2028.

That timeline captures the debate. Bulls see enrollment, a primary endpoint readout, and possible follow-on OS data as the clearest path to rerating. Bears can reasonably argue that meaningful clinical proof is still a long way off and that investors should stay alert to execution risk, including Delcath's history of unscheduled event filings and other event-driven disclosures.

What could change the narrative

• Steady accrual in both Phase 2 trials
• Any pre-readout data that reinforces the hepatic progression-free survival thesis
• Timely readouts around the planned 2028 window
• Fewer corporate updates that distract from the clinical path

What would weaken the thesis

• Slow enrollment or weaker-than-expected site activation
• Readout delays without interim support for the program
• Financial pressure that suggests expansion spending is outpacing cash generation
• Repeated filings or updates that keep the market focused on execution risk instead of clinical progress